A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
1. Diagnosed with PFIC (all types) who have been prescribed odevixibat (independently of the decision to enrol the participant in this registry) by their treating physician
2. On (or starting) active odevixibat treatment Note: Participants can remain in the registry during odevixibat treatment interruptions
You may not be if
1. Currently participating in a clinical trial with odevixibat
2. Currently participating in any interventional clinical trial for PFIC
3. Have any contraindication to odevixibat as per the approved label in South Korea.